Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine
12.10.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1.
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer. The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
1 Funding reference number FKZ 13GW0451A+B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Partners with Anthropic to Deliver AI-Powered Engineering Intelligence for Products and Manufacturing14.7.2026 18:28:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale. Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained. By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, A
Presidio Investors Announces Sale of ElevATE Semiconductor to Diodes Incorporated14.7.2026 17:56:00 EEST | Press release
Presidio Investors (“Presidio”), a lower middle market private equity firm, today announced that it has entered into a definitive agreement to sell ElevATE Semiconductor, Inc. (“ElevATE”) to Diodes Incorporated (Nasdaq: DIOD) in an all-cash transaction valued at $250 million. ElevATE, headquartered in San Diego, California, is a leading fabless designer of low-power, high-density integrated circuits for the automated test equipment (ATE) industry. The sale marks the successful realization of Presidio’s first continuation fund, which was formed in 2023 to extend the firm’s partnership with ElevATE and support the company’s next phase of growth. The acquisition of ElevATE by a leading global semiconductor company validates the strategy behind the continuation vehicle and delivers a strong outcome for the company, its employees, and Presidio’s investors. Presidio first invested in ElevATE in 2018, when the company was a small, founder-led team of analog chip designers serving the ATE mark
Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut14.7.2026 17:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition are heading to the 2026 Experimental Aircraft Association (EAA) AirVenture in Oshkosh, Wisconsin. Both aircraft will be on display for the first time at the show alongside a broad lineup of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714774354/en/ Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut “EAA AirVenture is one of the most important opportunities each year for us to connect with customers and the broader aviation community,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Being on the ground in Oshkosh allows us to showcase the breadth of our portfolio. Events like AirVenture also give us valuable face-to-face time to better understand how our customers operate and
Clearlake Capital Announces Partnership with Databricks to Advance AI-Enabled Investing and Portfolio Value Creation14.7.2026 17:00:00 EEST | Press release
Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities. Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage. “Data and A
Andersen Consulting Deepens Advisory Solutions in Turkey with ODS Consulting Group14.7.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services. Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation. “Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom